Schermer CR - Search Results

1

Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-analysis.

Lozano-Ortega G, Walker DR, Johnston K, Mickle A, Harrigan S, Rogula B, Kristy RM, Hairston JC, Schermer CR. Lozano-Ortega G, et al. Among authors: schermer cr. Drugs Aging. 2020 Nov;37(11):801-816. doi: 10.1007/s40266-020-00792-9. Drugs Aging. 2020. PMID: 32960422 Free PMC article.

2

Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study.

Szabo SM, Gooch K, Schermer C, Walker D, Lozano-Ortega G, Rogula B, Deighton A, Vonesh E, Campbell N. Szabo SM, et al. BMJ Open. 2019 May 5;9(5):e026391. doi: 10.1136/bmjopen-2018-026391. BMJ Open. 2019. PMID: 31061036 Free PMC article.

3

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Carlson KV, et al. Among authors: schermer cr. Adv Ther. 2019 Aug;36(8):1906-1921. doi: 10.1007/s12325-019-00994-7. Epub 2019 Jun 20. Adv Ther. 2019. PMID: 31222714 Free PMC article.

4

Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).

Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Wagg A, et al. Among authors: schermer cr. Eur Urol. 2020 Feb;77(2):211-220. doi: 10.1016/j.eururo.2019.10.002. Epub 2019 Nov 13. Eur Urol. 2020. PMID: 31733990 Free article. Clinical Trial.

5

Efficacy and Safety of Mirabegron versus Placebo Add-On Therapy in Men with Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Randomized, Phase 4 Study (PLUS).

Kaplan SA, Herschorn S, McVary KT, Staskin D, Chapple C, Foley S, Cambronero Santos J, Kristy RM, Choudhury N, Hairston J, Schermer CR. Kaplan SA, et al. Among authors: schermer cr. J Urol. 2020 Jun;203(6):1163-1171. doi: 10.1097/JU.0000000000000738. Epub 2020 Jan 2. J Urol. 2020. PMID: 31895002 Clinical Trial.

6

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.

Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Herschorn S, et al. Among authors: schermer cr. Drugs Aging. 2020 Sep;37(9):665-676. doi: 10.1007/s40266-020-00783-w. Drugs Aging. 2020. PMID: 32725584 Free PMC article. Clinical Trial.

7

Cardiovascular risk profile in individuals initiating treatment for overactive bladder - Challenges and learnings for comparative analysis using linked claims and electronic medical record databases.

Vonesh E, Gooch KL, Khangulov V, Schermer CR, Johnston KM, Szabo SM, Rumsfeld JS. Vonesh E, et al. Among authors: schermer cr. PLoS One. 2018 Oct 16;13(10):e0205640. doi: 10.1371/journal.pone.0205640. eCollection 2018. PLoS One. 2018. PMID: 30325968 Free PMC article.

8

Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.

Abbass IM, Caplan EO, Ng DB, Kristy R, Schermer CR, Bradt P, Collins JM, Chan WM, Suehs BT. Abbass IM, et al. Among authors: schermer cr. J Manag Care Spec Pharm. 2017 Jan;23(1):27-37. doi: 10.18553/jmcp.2017.23.1.27. J Manag Care Spec Pharm. 2017. PMID: 28025920 Free PMC article.

9

A prospective study of elderly initiating mirabegron versus antimuscarinics: Patient reported outcomes from the Overactive Bladder Satisfaction Scales and other instruments.

Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, Suehs BT. Bunniran S, et al. Among authors: schermer cr. Neurourol Urodyn. 2018 Jan;37(1):177-185. doi: 10.1002/nau.23271. Epub 2017 Mar 31. Neurourol Urodyn. 2018. PMID: 28370541

10

A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design, and methodology.

Rovner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, Gemmen E, Kristy RM, Gooch KL, Schermer CR. Rovner ES, et al. Among authors: schermer cr. Contemp Clin Trials. 2018 Jul;70:83-87. doi: 10.1016/j.cct.2018.05.006. Epub 2018 May 16. Contemp Clin Trials. 2018. PMID: 29777865 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

74 results

Search Page

Filters